Countries of activities
Belgium Finland France Greece Israel Italy Luxembourg Netherlands Norway Portugal Spain Sweden United Kingdom United States
Therapeutic Antibody Vaccine Cell therapy Immunotherapy Gene therapy In Vitro Diagnostic Biosimilar Biospecimen CMO CRO
Business Development Lead generation Business plan Sales force coaching B2B representation Services contract Distribution agreement Licensing deal Marketing Strategic Marketing Operational Marketing Communication Social Media Management In-bound marketing Market research Digital Marketing Corporate Set-up
Company set-up and development, Business plan, Design and creative communication, Lead generation, Growth hacking, Sales force coaching, Strategic marketing, In-bound marketing, Market research, B2B representation, Outsourcing deals management, Prospection for active biotech & pharmas entities evolving in human biospecimen, vaccine, gene therapy, cell therapy, immunotherapy, Contract Manufacturing, In-Vitro Diagnostic, Preclinical & Clinical research fields.
Business & Marketing Director
ImmuneHealth is a global and flexible biomarker CRO, ables to design, set-up, recruit, and conduct epidemiology studies for clinical biomarker panels validation, and provide immunomonitoring readouts (cell, gene and protein biomarkers). ImmuneHealth is able to provide QC methods with development from scratch, testing, qualification, validation, technical transfer, consulting and training activies through ELISA, ELISpot, Multiplex, rt(q)PCR, sequencing, pyrosequencing, FACS, ICS, microneutralization, binding assays, CAPS... ImmuneHealth's laboratories are ISO, GCLP, and GMP compliant. ImmuneHealth bridges the gap between R&D fundamental and clinical research, and translates basic immunology into medicine. Our versatile structure is able to provide proof of concept for new products and to discover and validate immunobiomarker panels. ImmuneHealth is currently engages into several European and regional projects (FEDER, FP6, FP7...) developing its own portfolio with a related network in the diagnostic and theranostic field. To be counted among our partners, GSK Vaccines, Genticel, Neovacs, Celyad, Theravectys, MaSTherCell, Celogos, DIAsource, Volition Rx, Immune Targeting Systems, Kitozyme, Imcyse, Delphi Genetics, IPG, Bio.be, OncoDNA, Ovogenics, CareSquare, Cetic, Probiox, Novasep, DNAlytics, IMI, InnaVirVax, Promethera Biosciences, Euroscreen, PX Biosolutions, Xenikos, Novartis, Crucell... In September 2016, ImmuneHealth assets have been acquired by Caprion Biosciences.
01/01/2012 - 08/01/2016
Chief Business Officer
Economies of scales and the increase of profitability are the key elements of our partners, facing huge competition for manufacturing costs. Risks that are linked to a stop of secretion are now banished. No change in your culture habits is required because BOOSTed and preBOOSTed cells can be cultured the same way as it is for the original cells, our Cell Fitness is based upon a unique series of cell physical treatments. AmplyCell has first developed BOOST stimulation technologies that stabilize and increase the productivity of hybridoma cell lines - from 5 to 10 times more - to address the hurdles of diagnostic market. At the end of 2015, AmplyCell has developed its technology to CHO cell lines allowing the GMP manufacturing of difficult-to-express New Biological Entities, applying its know-how to recombinant proteins and monoclonal antibodies in order to increase cell productivity by a minimum factor 3.
02/01/2015 - 08/01/2017
Preclinical CRO - Business Development
CER Groupe is a Belgian Preclinical CRO able to design a valuable and tailor-made solution for your in-vivo studies. Its main asset is to develop custom-made and flexible solutions, in an economic and timely manner for your R&D, GLP and GMP-compliant animal studies. Its state-of- the-art infrastructures offers a large range of non-clinical development services including, but not limited to : - development of administration route (IP, IM, IN…), - set-up of readouts (genetic, humoral and cellular), - mechanism of action of drugs, - drug efficacy evaluation, - adjuvant testing, such as in the field of cell therapy, cancerology, infectiology and immunology, that may involve micro-surgery, histology, imaging, and the access to specific humanized models. CER Groupe facilities are divided in two areas, a SPF/SOPF experimental animal maintenance facilities wing and BSL-2 and a BSL-3 compliant facilities area for studies involving pathogens which can cause serious and potentially-lethal diseases.
05/01/2015 - 08/01/2016
Business & Marketing Director, Board member
Word of mouth
Julien doesn't have any reviews, yet.Write your experience with Julien